Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2014 Sep 26;28(6):1055–1071. doi: 10.1016/j.hoc.2014.08.005

Table 1.

Patients and subgroups that should be considered for HSCT

EBMT criteria
Dreger et al. 200744

  • relapse within 24 months after having achieved a response with intensive treatment (purine analogue combinations, autoSCT)

  • detection of p53 abnormality and indication for treatment

  • fludarabine resistance: non-response or early relapse (<12 months after purine analogue-based therapy
iwCLL criteria
Hallek et al. 200845

  • resistant disease: failure to achieve CR/PR

  • relapse within 6 months of last treatment

  • detection of del(17p)-
Highest risk in risk category model
Zenz et al. 201246

  • Fludarabine refractory CLL

  • Early relapse (within24 mo) after FCR (or FCR-like) treatment

  • TP53 deletion/mutation and indication for treatment